GOOSE Society of Texas has invested in a chemical sensor company from Austin. Pexels

A Houston-based investment group has announced funding for a startup out of Austin that has the potential to disrupt multiple industries with its chemical sensor device.

GOOSE Society of Texas, a group of investors that invest over $50 million into early stage startups, led the $2.6 million round for Lantha Inc. The startup plans to use the funds for finalizing its commercial products, strategic hires, and expand its intellectual property. The device Lantha has created can detect solid-state chemicals, which can be used in a myriad of industries from pharmaceuticals and oil and gas to water and defense.

Jeff Smisek, former United Airlines CEO and founder of investment firm Flight Partners Management LLC, was the GOOSE investor to lead the deal. According to a news release, he will join Lantha's board of directors.

"Lantha is a great example of the GOOSE Society's investment thesis — a company with proprietary and disruptive technology, low capital costs, large addressable markets, speedy product development and high margins which can benefit from the vast experience and contacts of the GOOSE Society's investors," Smisek says in the release. "We are proud to lead this financing and look forward to working closely with Lantha's management and world class scientists as they build a powerhouse in the field-based chemical analysis market."

Simon Humphrey, associate professor of chemistry at the University of Texas, invented the handheld device that is faster, cheaper, and easier to use than traditional tools. Humphrey serves as CTO for the company, and Robert Toker is the CEO and chairman of Lantha.

"We have world class scientists, who are the inventors of our technology, and a strong founding team, and we've attracted a great group of investors led by Jeff Smisek and the GOOSE Society in Houston as well as several prominent investors associated with the University of Texas at Austin," Toker says. "... Partnering with GOOSE has materially improved our chances of success."

The Lantha investment represents the first time GOOSE has funded technology coming out of UT.

"We are excited about expanding GOOSE's investment efforts to UT and look forward to future collaborations and deals," says Samantha Lewis, director at GOOSE. Several high-profile investors from the UT community invested in Lantha's Series A Preferred Stock alongside GOOSE investors.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Austin company to bring AI-powered school to The Woodlands

AI education

Austin-based Alpha School, which operates AI-powered private schools, is opening its first Houston-area location in The Woodlands.

The 8,000-square-foot school, scheduled to be ready for the 2026-27 academic year, initially will serve students in kindergarten through eighth grade. Alpha says the school will offer “open workshop spaces and innovative classrooms that support personalized instruction, core academics, leadership development, and real-world life skills.”

Alpha sets aside two hours each school day for the AI-driven, self-paced study of core subjects like math, reading and science. The rest of each school day consists of life-skills workshops focusing on topics such as leadership and financial literacy.

Alpha’s school in The Woodlands has begun accepting applications for the 2026-27 school year. Annual tuition costs $40,000.

“The Woodlands is one of the most dynamic, forward-thinking communities in Texas, and Alpha is proud to bring

an innovative educational model that complements its strong academic foundation,” says Rachel Goodlad, head

of expansion for Alpha.

Founded in 2014, Alpha School combines adaptive technology-driven instruction with immersive life-skills workshops. Its model emphasizes mastery-based learning in core subjects alongside development of communication, critical thinking, financial literacy and leadership skills. It operates more than 15 schools across the country.

Elsewhere in Texas, Alpha operates schools in Austin, Brownsville, Fort Worth and Plano. Alpha also operates 12 Texas Sports Academy campuses in Texas, including locations in Houston, Pearland and Richmond, along with a NextGen Academy esports school in Austin, a school for gifted students in Georgetown, and lower-cost Nova Academy campuses in Austin and Bastrop.

Alpha has fans and critics. While supporters tout students’ high achievement rates, detractors complain about the high tuition and the AI-influenced depersonalization of education.

“Students and our country need to be in relationship with other human beings,” Randi Weingarten, president of the American Federation of Teachers, a teachers union, tells The New York Times. “When you have a school that is strictly AI, it is violating that core precept of the human endeavor and of education.”

Alpha co-founder MacKenzie Price, a podcaster and social media influencer, doesn’t share Weingarten’s views.

“Parents and teachers: We need to embrace this change,” Price wrote after President Trump signed an executive order promoting AI in schools.

The Times notes that Alpha doesn’t employ AI as a tutor or a supplement. Rather, the newspaper says, AI is “the school’s primary educational driver to move students through academic content.”

Houston researcher secures $1.7M to develop drug for aggressive form of breast cancer

cancer research

A University of Houston researcher has joined a $3.2 million effort to develop a new drug designed to attack a cancer-driving protein commonly found in triple-negative breast cancer.

Triple-negative breast cancer (TNBC) is one of the most difficult-to-treat forms of cancer and accounts for 10 percent to 15 percent of all breast cancer cases. The disease gets its name because tumors associated with it test negative for estrogen receptors, progesterone receptors and excess HER2 protein, making it difficult to target. Due to this, TNBC is often treated with general chemotherapy, which can come with negative side effects and drug resistance, according to UH.

UH College of Pharmacy research associate professor Wei Wang is developing a drug that can target the disease more specifically. The drug will target MDM2, a protein often overproduced in TNBC that also contributes to faster tumor growth.

Wang is working on a team led by Wei Li, director of the University of Tennessee Health Science Center College of Pharmacy’s Drug Discovery Center. She has received $1.7 million to support the research.

Wang and UH professor of pharmacology and toxicology Ruiwen Zhang have discovered a compound that can break down MDM2. In early laboratory models, the compound has shown the ability to shrink tumors.

Wang and Zhang will focus on understanding how the treatment works and monitoring its effectiveness in models that closely mirror human disease.

“We will study how the drug targets MDM2 and evaluate the most promising drug candidates to determine effective dosing, understand how the drug behaves in the body, compare it with existing treatments and assess early safety,” Wang said in a news release.

Li’s team at the University of Tennessee will be working on the chemistry and drug design end of the project.

“This work could lead to an entirely new class of therapies for triple-negative breast cancer,” Li added in the release. “We’re hopeful that by directly removing the MDM2 protein from cancer cells, we can help more patients respond to treatment regardless of their tumor type.”